# US 2025/0319212 A1 · Gadolinium-based compound, and mri contrast agent including same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0319212 A1
- Document ID: US20250319212A1
- Status: Published application
- Kind: A1
- Application number: 18/290,754
- Filed: 2022-07-21
- Published: 2025-10-16
- Earliest claimed: 2021-07-21
- Assignees: Kyungpook National University Industry-Academic Cooperation Foundation
- Applicants: Kyungpook National University Industry-Academic Cooperation Foundation
- Inventors: Yong Min CHANG; Bo Kyung SUNG
- Web page: https://patentgrep.com/patent/US20250319212A1

## CPC

- A61K 49/10: Organic compounds
- A61K 49/085: {conjugated systems}
- C07D 257/02: not condensed with other rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Disclosed is a gadolinium-based compound, and an MRI contrast agent including same. The gadolinium-based compound may be a DO3A-based gadolinium compound to which 4-hydroxybenzoic acid is bound. The MRI contrast agent may include the compound. Also disclosed is a pharmaceutical composition for preventing or treating neuroinflammatory diseases, wherein the composition comprises the compound or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A compound represented by a following Chemical Formula (1):
where L is *—(CH2)x—A1—(CH2)y—A2—(CH2)z—*,
each of x, y and z is an integer independently selected from 0 to 5,
each of A1 and A2 is at least one structure selected from a group consisting of a single bond, *—COO—*, *—CO—*, *—NH—*, *—CH2—*, *—CONH—*and *—O—*,
X has a structure represented by a following Chemical Formula (2):
where*is a binding site.

### Claim 2 (depends on 1)

The compound of claim 1, wherein A2 is *—NH—*.

### Claim 3 (depends on 2)

The compound of claim 2, wherein A1 is *—CONH—*.

### Claim 4 (depends on 3)

The compound of claim 3, wherein x is 1, y is 2, and z is 0.

### Claim 5 (depends on 1)

The compound of claim 1, wherein the compound is represented by a following Chemical Formula (3):

### Claim 6 (depends on 1)

The compound of claim 1, wherein the gadolinium (Gd) coordinates with at least one water molecule.

### Claim 7 (depends on 1)

The compound of claim 1, wherein the compound specifically binds to amyloid beta polymer (oligomeric Aβ) of a mammal.

### Claim 8 (depends on 1)

The compound of claim 1, wherein the compound has a relaxivity of 3.5 to 4.2 s−1.

### Claim 9 (depends on 1)

The compound of claim 1, wherein when the compound is injected intravenously, the compound flows through a blood-brain-barrier (BBB).

### Claim 10 (depends on 1)

An MRI contrast agent comprising the compound according to claim 1.

### Claim 11 (depends on 10)

The MRI contrast agent of claim 10, wherein the MRI contrast agent is used for diagnosis of degenerative brain diseases.

### Claim 12 (depends on 11)

The MRI contrast agent of claim 11, wherein the MRI contrast agent is used for diagnosis of Alzheimer's disease.

### Claim 13 (depends on 1)

A pharmaceutical composition for preventing or treating a neuroinflammatory disease, the composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13, wherein the neuroinflammatory disease is an inflammatory neurodegenerative brain disease.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, wherein the inflammatory neurodegenerative brain disease is selected from Alzheimer's disease or Parkinson's disease.
